BMO initiates Prime Medicine coverage with 'outperform'

Prime Medicine

09/10/2023 18:40

** Brokerage BMO initiates coverage of gene editing therapy
developer Prime Medicine  PRME.O  with an "outperform" rating,
sets PT at $19
    ** The price target represents a two-fold upside to the
stock's last close at $8.88
    ** BMO says the characteristics of high
versatility/specificity in the gene editing tech used by co
potentially offers broader applicability compared to other gene
editing approaches
        ** 5 of 6 brokerages rate the stock "buy" or higher, and
1 "hold"; their median PT is $22
    ** Including session moves, shares down ~54% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))